×
BridgeBio Pharma EBITDA 2018-2024 | BBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BridgeBio Pharma ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
BridgeBio Pharma EBITDA 2018-2024 | BBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BridgeBio Pharma ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$19B
Dr Reddy's Laboratories (RDY)
$12B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.1B
Supernus Pharmaceuticals (SUPN)
$2B
Taysha Gene Therapies (TSHA)
$434M
Personalis (PSNL)
$261M
Assembly Biosciences (ASMB)
$98M
Sol-Gel Technologies (SLGL)
$12M
Evoke Pharma (EVOK)
$7M
Teligent (TLGT)
$0M